Table 1.
Clinical and hematological characteristics of the patients recruited in the study
| Parameter | Classification | Subgroup of patients by treatment | p value | |
|---|---|---|---|---|
|
| ||||
| Untreated | Treated with Ibrutinib | |||
| Patients | % (number) | 27.8 (10) | 72.2 (26) | 0.01 |
| Age (years) | Median (min; max) | 66.5 (44; 82) | 69.0 (52; 91) | 0.91 |
| Sex | Male | 7 (19.44%) | 17 (47.22%) | 0.79 |
| Female | 3 (8.33%) | 9 (25%) | ||
| Stage (RAI Classification) | 1 | 19.44% | 2.77% | 0.003 |
| 2 | 8.33% | 47.22% | ||
| 3 | 2.77% | 8.33% | ||
| 4 | 0% | 11.1% | ||
| Cytogenetic mutations (TP53, 17p) | Present | 2.77% | 16.66% | 0.34 |
| No Present | 8.33% | 8.33% | ||
| Not determined | 16.66% | 47.22% | ||
| WBC count (×1000/uL) | Median (min; max) | 22.44 (5.35; 88.5) | 12.23 (3.3; 149.96) | 0.21 |
| Hemoglobin (g/dL) | Median (min; max) | 13.2 (10.5; 15) | 12.85 (6.3; 16.8) | 0.52 |
| Hematocrit (%) | Median (min; max) | 40.35 (33; 45,8) | 39.7 (21; 51) | 0.76 |
| Platelet Count (×1000/uL) | Median (min; max) | 174.5 (61; 273) | 164.00 (70; 337) | 0.75 |
| Lymphocytes count (×1000/uL) | Median (min; max) | 18.93 (1.1; 85) | 6.05 (0.83; 142.6) | 0.12 |
WBC = white blood cells. P values represent the significance of the differences between untreated and treated patients.